Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Syndax Pharmaceuticals Announces Updated Presentation Time at the Cantor Fitzgerald Global Healthcare Conference | ||
| By: PR Newswire Association LLC. - 20 Sep 2017 | Back to overview list |
|
WALTHAM, Mass., Sept. 20, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced an update to the time of the Company's presentation at the Cantor Fitzgerald Global Healthcare Conference. Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will now present on September 25, 2017 at 11:30 am EDT at the InterContinental New York Barclay Hotel. A live webcast of the Company's presentation can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time. About Syndax Pharmaceuticals, Inc. Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Our lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Given its potential ability to block the function of immune suppressive cells in the tumor microenvironment, entinostat is also being evaluated in combination with approved PD-1 antagonists. Ongoing Phase 1b/2 clinical trials combine entinostat with KEYTRUDA from Merck & Co., Inc. for non-small cell lung cancer, melanoma and colorectal cancer; with TECENTRIQ® from Genentech, Inc. for triple negative breast cancer; and with BAVENCIO® from Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. Our second product candidate, SNDX-6352, is a monoclonal antibody that blocks the CSF-1 receptor and may also block the function of immune suppressive cells in the tumor microenvironment. SNDX-6352 is being evaluated in Phase 1 clinical trials and is expected to be developed to treat a variety of cancers. Investor Contact Melissa Forst Media Contact SNDX-G View original content:http://www.prnewswire.com/news-releases/syndax-pharmaceuticals-announces-updated-presentation-time-at-the-cantor-fitzgerald-global-healthcare-conference-300522489.html SOURCE Syndax Pharmaceuticals 
|
||
|
||
 | Back to overview list | |